Latest research breakthroughs in the treatment of myotubular myopathy



Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs


Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy

Gene Therapy prolongs survival and restores function in murine and canine models
Preclinical Success in Two X-Linked Pediatric Diseases Sets Stage for Clinical Trials
Press Release;  Gene Therapy Rescues myotubular myopathy


Boston Children's Hospital's science and clinical innovation blog:  Gene therapy strengthens weak muscles in congenital myopathy

Major Breakthrough: The Miracle of Nibs

Nib's Legacy Lives On

MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers

JFF and Wake Forest University: Recap Last 10 Years at the Wake Forest Institute for Regenerative Medicine (Director: Anthony Atala)

Gene Therapy and MTM1 in the murine mouse

Below is a YouTube video created by Dr. Martin Childers at the University of Washington regarding the recent breakthroughs with the dog colony: